Skip to main content

New data on BeiGene's tislelizumab continue to show positive effect

Updated results from mid-stage studies evaluating BeiGene’s (BGNE +0.1%) PD-1 inhibitor tislelizumab continue to demonstrate a treatment effect. The data were presented at the Annual Meeting of the Chinese Society of Clinical Oncology in Xiamen.

No Comments yet!

Your Email address will not be published.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino